Vyacheslav Melnikov, MD
Nephrology · Corvallis, ORNPI 1780832998
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $319 and has fallen 59.6% since, to $129 in 2025.
Across 44 payments — averaging $21.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$138
- Vantive US Healthcare LLC$129
- Baxter Healthcare$125
- Travere Therapeutics, Inc.$90
- AstraZeneca$86
- Otsuka America Pharmaceutical, Inc.$75
- plus $292 from 11 others
What the payments were for
- Food & beverage$91197%
- Education$243%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 9 | $138 |
| Vantive US Healthcare LLC | 1 | $129 |
| Baxter Healthcare | 1 | $125 |
| Travere Therapeutics, Inc. | 7 | $90 |
| AstraZeneca(2 entities) | 5 | $86 |
| Otsuka America Pharmaceutical, Inc. | 4 | $75 |
| Genentech USA, Inc. | 3 | $47 |
| Bayer | 1 | $47 |
| Vifor Pharma, Inc. | 3 | $44 |
| OPKO Pharmaceuticals, LLC | 2 | $33 |
| Novo Nordisk | 1 | $29 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| GSK | 1 | $19 |
| Akebia Therapeutics Inc | 2 | $14 |
| BTG International Inc. | 1 | $14 |
| Fresenius USA Marketing, Inc. | 1 | $13 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Renal - PD$129
How this compares
$935 in reported general payments places this provider in the 80th percentile of 120 nephrology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 23 | $10,721 |
| Lanthanum Carbonate | 22 | $6,872 |
| Sevelamer Carbonate | 19 | $2,693 |
| Losartan Potassium | 53 | $579 |
| Furosemide | 25 | $295 |
| Lisinopril | 12 | $132 |
| Amlodipine Besylate | 11 | $122 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Corvallis
- Poojitha BeravolCorvallis$867
- Zain HaqCorvallis$764
- Pavan GonaCorvallis$735
- Tyler AndreaCorvallis$531
- Neil KumarRoseburg$532K
- Robert ProvenzanoPortland$45K
- Cyril KuriakoseTualatin$36K
- Nayan AroraPortland$23K
- Shalin SanghviSpringfield$20K
- Ramesh MarahattaSpringfield$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.